<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424201</url>
  </required_header>
  <id_info>
    <org_study_id>LagosSU</org_study_id>
    <nct_id>NCT02424201</nct_id>
  </id_info>
  <brief_title>Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.</brief_title>
  <official_title>Comparative Study on Effects of Sublingual Misoprostol in Addition to Standard Active Management of Third Stage of Labour in Low Risk Parturients in Lagos State University Teaching Hospital, Ikeja.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lagos State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lagos State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum haemorrhage is the leading cause of maternal haemorrhage globally. With active
      management of labour 3 to 16.5% of parturients still experience postpartum haemorrhage. Hence
      the need for an effective oxytocic in third stage of labour.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized doubleblind controlled trial involving 660 consenting
      pregnant women. Eligible subjects will be ransomised into 2 groups of 330 participants. All
      patients will receive the standard oxytocin 10 units as part of the active management of
      third stage of labour. However, the study group will be administered sublingual 400
      misoprostol while the control group will receive 2tablets of placebo (vitamin c). Measured
      mean blood loss will be comparee in the 2 groups using statistical analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean blood loss</measure>
    <time_frame>1 hour of delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with untowards effects</measure>
    <time_frame>1 hour of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Primary Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular oxytocin 10 units, 400 micrograms of misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>experimental</description>
    <arm_group_label>study</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin c</intervention_name>
    <description>control</description>
    <arm_group_label>control</arm_group_label>
    <other_name>ascorbic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton in longitudinal lie and cephalic presentation

        Exclusion Criteria:

          -  refusal of consents, multiple gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lagos State University</investigator_affiliation>
    <investigator_full_name>Oyedeko Muyideen Oladipo</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>uterine atony</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

